This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Liekens, S. Articles by Neyts, J. Search for Related Content PubMed PubMed Citation Articles by Liekens, S. Articles by Neyts, J.

A Novel Animal Model for Hemangiomas

Inhibition of Hemangioma Development by the Angiogenesis Inhibitor TNP-470¹

Rega Institute for Medical Research [S. L., M. V., E. D. C., J. N.] and Division of Histopathology [E. V.], University Hospitals, B-3000 Leuven, Belgium

Hemangiomas represent the most frequent tumors of infancy. However, the pathogenesis of these tumors is still largely unknown, and current treatment of juvenile hemangiomas remains unsatisfactory. Here we present a novel animal model to study proliferating hemangiomas and to evaluate the effect of angiostatic compounds on their growth. Intraperitoneal (i.p.) infection of 4-day-old rats with murine polyomavirus resulted in the development of multiple cutaneous, intramuscular (i.m.), and cerebral hemangiomas with 100% frequency. Histological examination of the brain revealed the formation of immature lesions as soon as 4 days postinfection (p.i.). The subsequent exponential growth of the hemangiomas, both in number and size, was associated with severe hemorrhage and anemia. The cerebral, cutaneous, and i.m. lesions consisted of blood-filled cysts, histologically similar to human cavernous hemangiomas and stained positive for proliferating cell nuclear antigen, urokinase-type plasminogen activator, and vascular endothelial growth factor. Mature cerebral hemangiomas also expressed von Willebrand factor. Cerebral lesions caused death of the untreated animals within 19.2 ± 1.1 days p.i. Remarkably fewer and smaller hemangiomas developed in animals that had been treated s.c. with the angiogenesis inhibitor TNP-470. Accordingly, TNP-470 (50 mg/kg), administered twice a week from 3 days p.i., significantly delayed tumor-associated mortality [mean day of death, 28.2 ± 3.3 (P < 0.001)]. Even if therapy was initiated when cerebral hemangiomas were already macroscopically visible (i.e., 9 days p.i.), a significant delay in hemangioma-associated mortality was observed. Also, the IFN-inducer polyinosinic-polycytidylic acid caused a delay of 9 days (P < 0.005) in tumor-associated mortality when administered i.p. at 5 mg/kg, twice a week, starting at day 3 p.i. The model described here may be useful for investigating (a) the angiogenic mechanism(s) underlying hemangioma progression; and (b) the effect of anti-angiogenic compounds on vascular tumor growth.

This article has been cited by other articles:

				E. Padalko, D. Nuyens, A. De Palma, E. Verbeken, J. L. Aerts, E. De Clercq, P. Carmeliet, and J. Neyts The Interferon Inducer Ampligen [Poly(I)-Poly(C12U)] Markedly Protects Mice against Coxsackie B3 Virus-Induced Myocarditis Antimicrob. Agents Chemother., January 1, 2004; 48(1): 267 - 274. [Abstract] [Full Text] [PDF]

				J. Wang, G. S. Sheppard, P. Lou, M. Kawai, N. BaMaung, S. A. Erickson, L. Tucker-Garcia, C. Park, J. Bouska, Y.-C. Wang, et al. Tumor Suppression by a Rationally Designed Reversible Inhibitor of Methionine Aminopeptidase-2 Cancer Res., November 15, 2003; 63(22): 7861 - 7869. [Abstract] [Full Text] [PDF]

				B. A. Ruggeri, C. Robinson, T. Angeles, J. Wilkinson IV, and M. L. Clapper The Chemopreventive Agent Oltipraz Possesses Potent Antiangiogenic Activity in Vitro, ex Vivo, and in Vivo and Inhibits Tumor Xenograft Growth Clin. Cancer Res., January 1, 2002; 8(1): 267 - 274. [Abstract] [Full Text] [PDF]

				S. Liekens, J. Neyts, E. De Clercq, E. Verbeken, D. Ribatti, and M. Presta Inhibition of Fibroblast Growth Factor-2-induced Vascular Tumor Formation by the Acyclic Nucleoside Phosphonate Cidofovir Cancer Res., July 1, 2001; 61(13): 5057 - 5064. [Abstract] [Full Text] [PDF]